Received Jan 1, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | GC4X3 | IM |
Photosensitivity; Pain in eyes; This non-serious case was reported by a other health professional and described the occurrence of photosensitivity in a 51-year-old female patient who received Herpes zoster (Shingrix) (batch number GC4X3) for prophylaxis. Concurrent medical conditions included anemia. Concomitant products included ferrous glycine sulfate (Fe). On 03-OCT-2025, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. On 03-OCT-2025, less than a day after receiving Shingrix, the patient experienced photosensitivity (Verbatim: Photosensitivity) and eye pain (Verbatim: Pain in eyes). The outcome of the photosensitivity was not resolved and the outcome of the eye pain was resolving. It was unknown if the reporter considered the photosensitivity and eye pain to be related to Shingrix. It was unknown if the company considered the photosensitivity and eye pain to be related to Shingrix. Additional Information: GSK Receipt Date: 31-DEC-2025 The patient was treated for photosensitivity and pain in eyes. The patient received Vitamins for anemia. The patient received 2nd dose on 05-DEC-2025.
Anemia
IRON